Who Paid My Doc
Zeeshan Haq
Retina Specialist Edina, MN Medical Doctor
NPI 1396278438 CMS profile 3827127
3601 W 76Th St Ste 300, Suite 300, Edina, MN 55435
General payments
$12,493
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$17,736
Through program year 2025, Zeeshan Haq of Edina, MN is reported in the CMS Open Payments database as having received $12,493 across 12 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $17,736 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 78th percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $10,997 | 10 | |
| 2024 | General | $1,480 | 1 | |
| 2023 | General | $16 | 1 |
Beside peers
- Zeeshan Haq
- Retina Specialist median
- Middle half of Retina Specialist
- National median
In program year 2025, general payments to Zeeshan Haq were reported at $10,997. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.
Show as a table
| Year | Zeeshan Haq | Retina Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $410 | $157–$1,517 | $163 |
| 2020 | $0 | $168 | $65–$778 | $114 |
| 2021 | $0 | $258 | $101–$1,161 | $132 |
| 2022 | $0 | $418 | $162–$1,488 | $149 |
| 2023 | $16 | $476 | $178–$1,312 | $160 |
| 2024 | $1,480 | $520 | $188–$1,372 | $164 |
| 2025 | $10,997 | $457 | $175–$1,079 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
693
Drug cost
$23,195
Branded share of claims
21.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Prednisolone Acetate | Generic | 242 | $12,732 | |
| Ketorolac Tromethamine | Generic | 174 | $3,922 | |
| Atropine Sulfate | Generic | 113 | $3,740 | |
| Brimonidine Tartrate | Generic | 16 | $1,016 | |
| Polymyxin B Sul-Trimethoprim Polymyxin B Sulf/Trimethoprim | Brand | 105 | $722 | |
| Valacyclovir Valacyclovir Hcl | Brand | 20 | $685 | |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | Brand | 23 | $379 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$2,569,475
Medicare patients
722
Services billed
35,315
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Arthritis | 39% | |
| Diabetes | 31% | |
| Chronic kidney disease | 28% | |
| Ischemic heart disease | 24% | |
| Atrial fibrillation | 23% | |
| Depression | 20% | |
| Heart failure | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, aflibercept, 1 mg J0178 | Office | 139 | 1,188 | $782,525 |
| Injection, faricimab-svoa, 0.1 mg J2777 | Office | 113 | 26,520 | $726,802 |
| Injection, aflibercept hd, 1 mg J0177 | Office | 56 | 1,712 | $453,243 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 | Office | 51 | 969 | $180,667 |
| Injection, ranibizumab, 0.1 mg J2778 | Office | 12 | 155 | $19,562 |
| Injection, bevacizumab, 10 mg J9035 | Office | 57 | 163 | $8,970 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Retina Specialist in Minnesota
Related records
Retina Specialist in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Retina Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.